|
Name |
12E,15R-5-hydroxy-3-methoxy-16-methyl-8,9,10,11,14,15-hexahydro-1H-benzo[c][1]oxacyclodocecin-1-one
|
Molecular Formula | C17H22O4 | |
IUPAC Name* |
(4R,6E)-14-hydroxy-16-methoxy-4-methyl-3-oxabicyclo[10.4.0]hexadeca-1(12),6,13,15-tetraen-2-one
|
|
SMILES |
C[C@@H]1C/C=C/CCCCC2=C(C(=CC(=C2)O)OC)C(=O)O1
|
|
InChI |
InChI=1S/C17H22O4/c1-12-8-6-4-3-5-7-9-13-10-14(18)11-15(20-2)16(13)17(19)21-12/h4,6,10-12,18H,3,5,7-9H2,1-2H3/b6-4+/t12-/m1/s1
|
|
InChIKey |
MRKJWGWVFJOTLX-FVOPLDGLSA-N
|
|
Synonyms |
12E,15R-5-hydroxy-3-methoxy-16-methyl-8,9,10,11,14,15-hexahydro-1H-benzo[c][1]oxacyclodocecin-1-one
|
|
CAS | NA | |
PubChem CID | 139591595 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 290.4 | ALogp: | 4.3 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 21 | QED Weighted: | 0.618 |
Caco-2 Permeability: | -4.733 | MDCK Permeability: | 0.00003270 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.15 |
30% Bioavailability (F30%): | 0.673 |
Blood-Brain-Barrier Penetration (BBB): | 0.099 | Plasma Protein Binding (PPB): | 98.63% |
Volume Distribution (VD): | 1.372 | Fu: | 1.36% |
CYP1A2-inhibitor: | 0.972 | CYP1A2-substrate: | 0.697 |
CYP2C19-inhibitor: | 0.928 | CYP2C19-substrate: | 0.28 |
CYP2C9-inhibitor: | 0.74 | CYP2C9-substrate: | 0.97 |
CYP2D6-inhibitor: | 0.935 | CYP2D6-substrate: | 0.889 |
CYP3A4-inhibitor: | 0.699 | CYP3A4-substrate: | 0.096 |
Clearance (CL): | 5.357 | Half-life (T1/2): | 0.823 |
hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.192 |
Drug-inuced Liver Injury (DILI): | 0.331 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.008 | Maximum Recommended Daily Dose: | 0.918 |
Skin Sensitization: | 0.938 | Carcinogencity: | 0.163 |
Eye Corrosion: | 0.024 | Eye Irritation: | 0.817 |
Respiratory Toxicity: | 0.275 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002298 | 0.662 | D07MGA | 0.304 | ||||
ENC005004 | 0.662 | D0J4IX | 0.287 | ||||
ENC005006 | 0.644 | D0L1JW | 0.287 | ||||
ENC005001 | 0.644 | D03SKD | 0.278 | ||||
ENC002425 | 0.639 | D0X5KF | 0.271 | ||||
ENC003715 | 0.622 | D09PJX | 0.255 | ||||
ENC002387 | 0.587 | D0R9VR | 0.253 | ||||
ENC003318 | 0.556 | D02LZB | 0.252 | ||||
ENC002946 | 0.494 | D04TDQ | 0.252 | ||||
ENC005476 | 0.494 | D0G4YT | 0.250 |